The Serendipitous Story of SGLT2 Inhibitors in Heart Failure
Key result
SGLT2 inhibitors have demonstrated significant benefits, including a 35% relative risk reduction with empagliflozin, in reducing hospitalization for heart failure in patients with type 2 diabetes.
Why the study?
Do SGLT2 inhibitors reduce heart failure hospitalization and cardiovascular death in patients with type 2 diabetes mellitus?
Population
Patients with type 2 diabetes mellitus with and without established atherosclerotic vascular disease (ASCVD)
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
SGLT2 inhibitors provide consistent benefits in reducing heart failure hospitalizations and cardiovascular death in patients with type 2 diabetes mellitus, regardless of established ASCVD.
Structured PICO
Do SGLT2 inhibitors reduce heart failure hospitalization and cardiovascular death in patients with type 2 diabetes mellitus?
P
Population
Patients with type 2 diabetes mellitus with and without established atherosclerotic vascular disease (ASCVD)
I
Intervention
SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin)
O
Outcome
Hospitalization for heart failure (HHF) or the composite of HHF or cardiovascular deathcomposite
SGLT2 inhibitors provide consistent benefits in reducing heart failure hospitalizations and cardiovascular death in patients with type 2 diabetes mellitus, regardless of established ASCVD.
Cite This Study
Verma et al. (2019) conducted an editorial in Type 2 diabetes mellitus and heart failure. SGLT2 inhibitors was evaluated. SGLT2 inhibitors have demonstrated significant benefits, including a 35% relative risk reduction with empagliflozin, in reducing hospitalization for heart failure in patients with type 2 diabetes.